Novartis AG
Company & revenue
About Novartis AG
Financial breakdown: year ended 2025-12-31
Who they are
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Brands & revenue mix
Selective, oral cyclin-dependent inhibitor of kinases 4 and 6 (CDK4/6) for breast cancer.
Separate brand revenue is not available in this research.Source
Anti-CD20 monoclonal antibody for targeted depletion of B-cells.
Separate brand revenue is not available in this research.Source
Radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer.
Separate brand revenue is not available in this research.Source
Oral combination therapy for BRAF V600 mutation cancers.
Separate brand revenue is not available in this research.Source
Oral inhibitor of JAK1 and JAK2 tyrosine kinases.
Separate brand revenue is not available in this research.Source
Oral kinase inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia.
Separate brand revenue is not available in this research.Source
Somatostatin analogs for acromegaly and neuroendocrine tumors.
Separate brand revenue is not available in this research.Source
Tyrosine kinase inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Customer concentrationPREMIUM
Novartis does not disclose specific customer concentration figures, noting that it operates in a global market with a broad range of stakeholders including healthcare providers and patients, as of the fiscal year ended December 31, 2025.
Business relationships & partnershipsPREMIUM
- Incyte Corporation — Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization in the indications of oncology, hematology and GvHD outside the US.Source
- Astex Pharmaceuticals — Kisqali was developed by Novartis's Biomedical Research organizational unit under a research collaboration with Astex Pharmaceuticals.Source
- Shionogi & Co., Ltd. — Novartis has worldwide exclusive rights to develop, manufacture, and commercialize trametinib granted by Shionogi & Co., Ltd. (as successor to Japan Tobacco Inc.).Source
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
44
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
70
Strong
Financial Strength
58
Business Quality / Moat
70
Management
100
Growth Quality
39
Risk / Durability
93
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
40
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
42/100
Building Historical Record
Model Score 42/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for NVS
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can NVS maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is NVS's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is NVS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of NVS's score?
Essential Investment Snapshot
Wall Street Score
44
Opportunity Score
40
Market Cap
$268.00B
P/E Ratio
21.3
EPS
$6.66
52-Week High
$170.46
52-Week Low
$121.57
Beta
0.46
Intrinsic Value
$163.72
Analyst Target
$136.00
Shares Outstanding
1.96B
Total Revenue
$55.63B
Total Debt
$49.01B
Dividend Yield
3.36%
Liquidation Value / Share
$21.46
Annual Dividend
$4.74
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for NVS
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on NVS.
What the Bulls Say
- +Material partnership/catalyst: Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization in the indications of oncology, hematology and GvHD outside the US.
- +Material partnership/catalyst: Kisqali was developed by Novartis's Biomedical Research organizational unit under a research collaboration with Astex Pharmaceuticals.
- +Material partnership/catalyst: Novartis has worldwide exclusive rights to develop, manufacture, and commercialize trametinib granted by Shionogi & Co., Ltd. (as successor to Japan Tobacco Inc.).
- +Product opportunity: Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
What the Bears Say
No strong bearish data point is currently available.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
43
Jul 24, 2026
Change
+1.6
points
Current Score
44
Oct 1, 2026
Category Changes
NVS increased 1.6 points because Capital improved by 6 points, Valuation improved by 7.7 points.
Positive Contributors
- + Capital improved by 6 points
- + Valuation improved by 7.7 points
Projected Score
Projected Score
38
Projected Change
-6.0%
Preliminary comparable-period financial changes suggest decline of approximately 6.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$141.00
Intrinsic Value
$163.72
Difference
−$22.72
-13.9% vs IV
Margin of Safety
13.9%
Related Companies
Drug Manufacturers - GeneralNews
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial